Xenetic Biosciences Inc (XBIO)

$2.81 +0.24 (9.46%)
Market Cap 6.43M
Revenue (ttm) 2.50M
Net Income (ttm) -3.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -158.40%
Debt to Equity Ratio 0.00
Volume 66,400
Avg Vol 24,804
Day's Range N/A - N/A
Shares Out 2.29M
Stochastic %K 88%
Beta 2.26
Analysts Strong Buy
Price Target $40.00

Company Profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carc...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 778 7720
Address:
945 Concord Street, Framingham, United States
User32548888
User32548888 Mar. 12 at 10:23 PM
$INO I just need a freak pump like how $XBIO did last year to get me off hook.
0 · Reply
aafetygod
aafetygod Mar. 4 at 10:00 PM
$XBIO 8+ soon.
0 · Reply
TheBlackBerrry
TheBlackBerrry Mar. 4 at 2:53 PM
$VCIG SCAM LIKE $XBIO FROM BACK IN NOVEMBER> SAME SCAM>
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 27 at 6:52 PM
$XBIO it’s starting
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 25 at 4:40 PM
$XBIO loading here before the pop
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 24 at 5:57 PM
$XBIO getting closer every to breaking through the cloud
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 3:05 AM
$XBIO RSI: 51.48, MACD: -0.0240 Vol: 0.17, MA20: 2.28, MA50: 2.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 3:10 PM
$XBIO Current Stock Price: $2.28
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 19 at 4:50 PM
$XBIO also the balance sheet is decent for a a sm biotech. No runaway crazy burn rate happening.
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 19 at 3:03 PM
$XBIO loaded here. The chart looks good
0 · Reply
Latest News on XBIO
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Mar 13, 2026, 8:00 AM EDT - 2 days ago

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Dec 11, 2025, 5:00 PM EST - 3 months ago

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Nov 19, 2025, 8:45 AM EST - 4 months ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 8:45 AM EST - 4 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Oct 10, 2025, 9:30 AM EDT - 5 months ago

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Jul 30, 2025, 9:00 AM EDT - 8 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Jul 23, 2025, 8:30 AM EDT - 8 months ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Jul 8, 2025, 9:00 AM EDT - 8 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 8:05 AM EDT - 10 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Apr 9, 2025, 9:15 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Feb 27, 2025, 9:15 AM EST - 1 year ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Dec 16, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Dec 5, 2024, 8:45 AM EST - 1 year ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Nov 21, 2024, 8:30 AM EST - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 8:30 AM EST - 1 year ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 12, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 22, 2024, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Jan 17, 2024, 9:00 AM EST - 2 years ago

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Nov 10, 2023, 8:35 AM EST - 2 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Oct 11, 2023, 9:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Aug 11, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

Jul 5, 2023, 8:45 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 12, 2023, 12:30 PM EDT - 3 years ago

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 4:30 PM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

May 4, 2023, 8:35 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

May 3, 2023, 8:35 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

Mar 23, 2023, 7:35 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

Mar 16, 2023, 11:00 AM EDT - 3 years ago

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Mar 16, 2023, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Jan 17, 2023, 8:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Jan 5, 2023, 8:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Nov 16, 2022, 8:35 AM EST - 3 years ago

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 7:05 AM EST - 3 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

Oct 11, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

VNRX

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

Oct 4, 2022, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 12, 2022, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

Aug 2, 2022, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

VNRX

User32548888
User32548888 Mar. 12 at 10:23 PM
$INO I just need a freak pump like how $XBIO did last year to get me off hook.
0 · Reply
aafetygod
aafetygod Mar. 4 at 10:00 PM
$XBIO 8+ soon.
0 · Reply
TheBlackBerrry
TheBlackBerrry Mar. 4 at 2:53 PM
$VCIG SCAM LIKE $XBIO FROM BACK IN NOVEMBER> SAME SCAM>
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 27 at 6:52 PM
$XBIO it’s starting
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 25 at 4:40 PM
$XBIO loading here before the pop
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 24 at 5:57 PM
$XBIO getting closer every to breaking through the cloud
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 3:05 AM
$XBIO RSI: 51.48, MACD: -0.0240 Vol: 0.17, MA20: 2.28, MA50: 2.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 3:10 PM
$XBIO Current Stock Price: $2.28
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 19 at 4:50 PM
$XBIO also the balance sheet is decent for a a sm biotech. No runaway crazy burn rate happening.
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 19 at 3:03 PM
$XBIO loaded here. The chart looks good
0 · Reply
CaptainStockWolf
CaptainStockWolf Feb. 17 at 5:24 PM
$XBIO watching here 🤔
0 · Reply
rispi
rispi Feb. 17 at 9:16 AM
@Merlintrader have you an analysis on $XBIO ? she seems ready for another spike. Thanks
0 · Reply
BullsOnDan
BullsOnDan Feb. 17 at 8:54 AM
$XBIO Pre-revenue biotech; early-stage
0 · Reply
topstockalerts
topstockalerts Feb. 12 at 7:48 PM
$XBIO Ready for another push higher? Buyers haven’t backed off. Momentum still favors the upside 📈.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 11 at 11:22 AM
Why Did UPB Stock Pop 20% In Pre-Market Today? $UPB $XBI $XBIO $BBC https://stocktwits.com/news/equity/markets/why-did-upb-stock-pop-in-pre-market-today/cZb6OdwR4qS
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 1:06 PM
$XBIO Current Stock Price: $2.12
0 · Reply
topstockalerts
topstockalerts Jan. 27 at 9:29 PM
After Hours Top Gainers PT2 $NWGL $CYPH $XBIO $FFIV $LHAI
0 · Reply
IndieJones
IndieJones Jan. 22 at 8:34 PM
$XBIO This went crazy a few months back and went into the $20 s in after hours trading, hopefully we get another run like that soon?
0 · Reply
BdGtradeR
BdGtradeR Jan. 20 at 4:36 PM
$XBIO
0 · Reply
cuzz202
cuzz202 Jan. 6 at 2:57 AM
$XBIO
0 · Reply
JovianJest
JovianJest Dec. 27 at 12:56 PM
$XBIO Positioning reflects caution while awaiting confirmable progress; capital allocation choices will face heightened scrutiny — stable fundamentals would matter more than macro swings. Durability will separate winners from speculation.
0 · Reply
aafetygod
aafetygod Dec. 20 at 1:20 PM
$XBIO $LRHC i'm planning to buy XBIO after my LRHC play. My PT1 is 2.75 and PT2 is 3.45. Haha... I just hope it stays put until I get in... doubt it though, right?
0 · Reply